Shreshth Gandhi

Shreshth Gandhi

Auto-generated profile, based on publicly available information

Shreshth Gandhi

Deep Genomics

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAlbi Celaj
Albi Celaj
AGAlice Jiexin Gao
Alice Jiexin Gao
TLTammy T.Y. Lau
Tammy T.Y. Lau
EHErle M. Holgersen
Erle M. Holgersen
ALAlston Lo
Alston Lo
BFBrendan J. Frey
Brendan J. Frey
Accurately modeling and predicting RNA biology has been a long-standing challenge, bearing significant clinical ramifications for variant interpretation and the formulation of tailored therapeutics. We describe a foundation model for RNA biology, “BigRNA”, which was trained on thousands of genome-matched datasets to predict tissue-specific RNA expression, splicing, microRNA sites, and RNA binding protein specificity from DNA sequence. Unlike approaches that are restricted to missense variants, BigRNA can identify pathogenic non-coding variant effects across diverse mechanisms, including polyadenylation, exon skipping and intron retention. BigRNA accurately predicted the effects of steric blocking oligonucleotides (SBOs) on increasing the expression of 4 out of 4 genes, and on splicing for 18 out of 18 exons across 14 genes, including those involved in Wilson disease and spinal muscular atrophy. We anticipate that BigRNA and foundation models like it will have widespread applications in the field of personalized RNA therapeutics.

23 October 2025 in bioRxiv
Verified
Preprint
Open access
SGShreshth Gandhi
Shreshth Gandhi
FJFarnoosh Javadi
Farnoosh Javadi
VSValentine Svensson
Valentine Svensson
UKUmair Khan
Umair Khan
MJMatthew G. Jones
Matthew G. Jones
NANima Alidoust
Nima Alidoust
Foundation models have transformed natural language processing and computer vision, yet their potential in single-cell biology—particularly for complex diseases such as cancer— remains underexplored. We present Tahoe-x1 (Tx1), a family of perturbation-trained single-cell foundation models with up to 3 billion parameters. Tx1 is pretrained on large-scale single-cell transcriptomic datasets, including the Tahoe-100M perturbation compendium, and fine-tuned for cancer-relevant tasks. Through architectural optimizations, data loader refinements, and efficient training strategies, Tx1 achieves 3–30× higher compute efficiency than prior implementations of cell-state models. Tx1 jointly learns representations of genes, cells, and compounds using a masked-expression generative objective that incorporates a drug token, enabling flexible adaptation to diverse downstream applications. We evaluate Tx1 across four key disease-relevant benchmarks: (1) prediction of overall and context-specific gene essentiality, (2) identification of genes contributing to the hallmarks of cancer, (3) cell-type classification, and (4) prediction of perturbation responses in held-out cellular contexts. Tx1 achieves state-of-the-art performance across all tasks. We release pretrained checkpoints, training code, and evaluation workflows to accelerate the development of perturbation-trained single-cell foundation models for applications in precision oncology and beyond.

12 June 2026 in bioRxiv
Verified
Preprint
Open access
VSValentine Svensson
Valentine Svensson
UKUmair Khan
Umair Khan
HHHamed Heydari
Hamed Heydari
AUAirol A. Ubas
Airol A. Ubas
NTNicole Thomas
Nicole Thomas
SGShreshth Gandhi
Shreshth Gandhi
Predicting how cells, tissues, and patients will respond to a drug, cytokine, or genetic perturbation is central to biological and clinical reasoning. The practical goal is to estimate the analysis-ready readouts that support this reasoning: which cellular responses are context-dependent, which perturbations reveal shared or divergent mechanisms, and which observations should become the basis for the next experiment. Here we introduce Rhaister, a perturbation-response predictor that operates directly on screen-level summary statistics. By measuring just a few perturbations in a new biological context, Rhaister predicts the unmeasured perturbations by learning how response patterns vary across reference contexts. This formulation applies to both fine-grained molecular readouts, such as transcriptional responses from Tahoe-100M or other large perturbation screen, or on phenotypic endpoints. To train and apply Rhaister on phenotypic endpoints we created Emerald Bay, a purpose-built Tahoe dataset that unifies multi-day cancer drug perturbation, pooled Mosaic tumor contexts, and paired transcriptomic response measurements*. Across these settings, Rhaister matches or exceeds substantially more expensive virtual-cell models, often achieving the highest values possible in evaluation metrics, while training in seconds and running predictions in milliseconds. On Emerald Bay, Rhaister predicts context-specific drug phenotypes from sensitivity measurements alone and improves further when including transcriptomic information. We also introduce Rhaister-O, predicting drug responses in new contexts from baseline expression alone and, to our knowledge, provides the first zero-shot model for this task. Rhaister establishes summary-statistic perturbation modeling as a fast, interpretable framework for predicting biological response across new contexts. *: https://huggingface.co/collections/tahoebio/rhaister

16 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
BKBhargav Kanuparthi
Bhargav Kanuparthi
SPSara E. Pour
Sara E. Pour
SFScott D. Findlay
Scott D. Findlay
OWOmar Wagih
Omar Wagih
JGJahir M. Gutierrez
Jahir M. Gutierrez
BFBrendan J. Frey
Brendan J. Frey
MicroRNAs and RNA binding proteins are crucial elements of post-transcriptional gene regulation, which governs the fate of mRNA molecules in the cell. However, the landscape of these regulatory interactions, particularly across different mammalian cell types, remains underexplored. We describe REPRESS, a deep learning model that predicts cell-type-specific microRNA binding and mRNA degradation directly from RNA sequence. REPRESS was trained on AGO2-CLIP, miR-eCLIP and Degradome-Seq data profiling millions of microRNA binding and mRNA degradation sites across multiple cell types in human and mouse. It reveals biology that other state-of-the-art methods did not, such as identifying repressive non-canonical miRNA target sites and decoding the regulatory effects of sequence context and miRNA binding site multiplicity. REPRESS outperforms other advanced methods and neural architectures on a comprehensive suite of seven orthogonal tasks, including identifying genetic variants that affect microRNA binding, predicting out-of-distribution data from massively parallel reporter assays, and predicting canonical and non-canonical miRNA mediated repression. To demonstrate the general utility of REPRESS, we show that it provides insights into novel biology and the design of RNA therapeutics. Code is available at : https://github.com/deepgenomics/repress